Log in

Relevant bibliographies by topics / Lornoxicam

Contents

Journal articles
Book chapters
Conference papers

Academic literature on the topic 'Lornoxicam'

Author: Grafiati

Published: 3 June 2025

Last updated: 31 July 2025

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Consult the lists of relevant articles, books, theses, conference reports, and other scholarly sources on the topic 'Lornoxicam.'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Journal articles on the topic "Lornoxicam"

1

Drais, Hayder Kadhim. "Transdermal Delivery of Lornoxicam Hybrid Nanogel: Design, Preparation, Characterization, and In-Vitro Diffusion Evaluation." Iraqi Journal of Industrial Research 10, no. 2 (2023): 98–104. http://dx.doi.org/10.53523/ijoirvol10i2id289.

Full text

Abstract:

Lornoxicam was practically water insoluble and a nonsteroidal anti-inflammatory therapeutic agent thus associated with gastrointestinal tract (GIT) side effects. Lipid polymer hybrid nanocarriers (LPHNs)-based transdermal nanogel of lornoxicam was formulated to increase solubility of lornoxicam and sustained lornoxicam release that lead to eliminate GIT related side effect, prolong therapeutic activity and improve patient compliance .The lornoxicam LPHNs formulations (LH1-LH6) were prepared by microwaves based method. The conventional gel of lornoxicam (G) was prepared by solvent diffusion met

APA, Harvard, Vancouver, ISO, and other styles

2

Hussen, Jamal, Mahmoud Kandeel, Turke Shawaf, Abdullah I. A. Al-Mubarak, Naser A. Al-Humam, and Faisal Almathen. "Immunomodulatory Effects of the Cyclooxygenase Inhibitor Lornoxicam on Phenotype and Function of Camel Blood Leukocytes." Animals 11, no. 7 (2021): 2023. http://dx.doi.org/10.3390/ani11072023.

Full text

Abstract:

(1) Background: Lornoxicam is a nonsteroidal anti-inflammatory drug (NSAID) with analgesic, antiphlogistic and antipyretic effects. The improved tolerance of lornoxicam due to the relatively shorter elimination half-life in comparison to other members of the oxicams may favor its application in the management of pain and inflammation in race dromedary camels. There are no studies conducted yet on the immunomodulatory or immunotoxilogic effect of lornoxicam in camels. Therefore, the current study aimed to evaluate the immunomodulatory effects of the cyclooxygenase inhibitor lornoxicam on some p

APA, Harvard, Vancouver, ISO, and other styles

3

&NA;. "Lornoxicam." Reactions Weekly &NA;, no. 1179 (2007): 22–23. http://dx.doi.org/10.2165/00128415-200711790-00067.

Full text

APA, Harvard, Vancouver, ISO, and other styles

4

Balfour, Julia A., Andrew Fitton, and Lee B. Barradell. "Lornoxicam." Drugs 51, no. 4 (1996): 639–57. http://dx.doi.org/10.2165/00003495-199651040-00008.

Full text

APA, Harvard, Vancouver, ISO, and other styles

5

Saračević, Amela, and Fahir Bečić. "The synergistic antinociceptive effect of lornoxicam in combination with tramadol." Journal of Health Sciences 3, no. 3 (2013): 238–42. http://dx.doi.org/10.17532/jhsci.2013.114.

Full text

Abstract:

Introduction: One of the most important priorities in therapy is pain control. Therefore, many different groups of drugs are being used for this purpose, primarily opioid analgesics and non-steroidal anti-inflammatory drugs (NSAIDs). Opioid analgesic tramadol, by binding to specific receptors, modulates the perception and response to painful stimuli and inhibits transmitting and further processing of pain impulses. Lornoxicam, which belongs to the oxicam class of NSAIDs, is a non-selective cyclooxygenase inhibitor with strong analgesic and anti-inflammatory effects, and better tolerance profil

APA, Harvard, Vancouver, ISO, and other styles

6

Abraham, Sindhu, Rajamanickam Deveswaran, Sharon Furtado, Srinivasan Bharath, and Varadharajan Madhavan. "Application of Hydrotropic Solubilization in Spectrophotometric Estimation of Lornoxicam from Tablets." International Scholarly Research Notices 2014 (October 29, 2014): 1–4. http://dx.doi.org/10.1155/2014/810128.

Full text

Abstract:

Lornoxicam is a selective cyclooxygenase-1 and cyclooxygenase-2 inhibitor that exhibits anti-inflammatory, analgesic, and antipyretic activities. It is used in osteoarthritis and rheumatoid arthritis; and in treatment of postoperative pain and primary dysmenorrhoea. Lornoxicam is completely insoluble in water but soluble in alkaline solutions. Hydrotropic solubilization is a technique used to increase the aqueous solubility of poorly water-soluble drugs and the present study was aimed at developing a hydrotropic technique to increase the solubility of lornoxicam, using 2 M sodium benzoate as t

APA, Harvard, Vancouver, ISO, and other styles

7

Patel, Tushar H., Umang H. Shah, Manan A. Raval, and Samir G. Patel. "DEVELOPMENT AND VALIDATION OF RP-HPLC METHOD FOR SIMULTANEOUS ESTIMATION OF LORNOXICAM AND TOLPERISONE HYDROCHLORIDE IN BULK DRUG AND COMBINED DOSAGE FORM." Indian Drugs 59, no. 03 (2022): 47–53. http://dx.doi.org/10.53879/id.59.03.12032.

Full text

Abstract:

A Reverse Phase High Performance Liquid Chromatographic method was developed and validated for the simultaneous estimation of lornoxicam and tolperisone hydrochloride in bulk drug and its combined dosage form. Chromatographic separation was carried out isocratically by reverse phase water enable C18 column (250 mm × 4.6 mm, 5.0 μ) using methanol: acetonitrile: water in ratio of 60:30:10 (V/V/V, pH adjusted to 3.0 with orthophosphoric acid) as a mobile phase at a flow rate of 1 mg min-1 and UV visible detection at wavelength of 285 nm. The retention times for tolperisone hydrochloride and lorno

APA, Harvard, Vancouver, ISO, and other styles

8

El-Bahr, Sabry M., Rabab R. Elzoghby, Mohammed A. Alfattah, Mahmoud Kandeel, and Ahlam F. Hamouda. "Aqueous Ginger (Zingiber officinale) Extract Ameliorates the Harmful Effects of High-Dose Lornoxicam in Albino Male Rats." BioMed Research International 2022 (August 2, 2022): 1–15. http://dx.doi.org/10.1155/2022/1546734.

Full text

Abstract:

Lornoxicam is a potent oxicam-class nonsteroidal anti-inflammatory drug (NSAID) with analgesic, anti-inflammatory, and antipyretic effects. Its impacts on many biological functions are not fully understood. We measured various biomarkers in male albino rats provided an oral aqueous ginger extract before IM administration of therapeutic and 2× the therapeutic doses of lornoxicam. The aqueous ginger plant extract was characterized by mass spectroscopy, and its effects were determined by examining free radical scavenging activity, blood parameters, renal and hepatic function, semen quality, proin

APA, Harvard, Vancouver, ISO, and other styles

9

Puranik, Manisha P., Debarshi Kar Mahapatra, Rajendra O. Ganjiwale, and Shital D. Tiple. "Development and Validation of FTIR Spectroscopic Method for the Quantitative Estimation of Lornoxicam in Tablet Dosage Form." INTERNATIONAL JOURNAL OF PHARMACEUTICAL QUALITY ASSURANCE 15, no. 03 (2024): 1633–37. http://dx.doi.org/10.25258/ijpqa.15.3.81.

Full text

Abstract:

Lornoxicam is available in the market as a solid dosage form, particularly tablets. Liquid chromatography has been the recommended assay procedure for lornoxicam in various pharmacopeias. While going through the literature, it was observed that for the analysis of lornoxicam, no FTIR based method was found. The present study involves the development of a novel, rapid, superior, labor-free, non-destructive, and economic FTIR-based analytical technique for the analysis of lornoxicam in both bulk and tablet formulations. International Council validated the method for Harmonization of Technical Re

APA, Harvard, Vancouver, ISO, and other styles

10

Bansal, Abanesh kumar, and Vishal Pande. "Development and Evaluation of Dual Cross-Linked Pulsatile Beads for Chronotherapy of Rheumatoid Arthritis." Journal of Pharmaceutics 2013 (December 18, 2013): 1–8. http://dx.doi.org/10.1155/2013/906178.

Full text

Abstract:

In the present investigation, pulsatile release beads were prepared by ionic gelation technique. Lornoxicam dual cross-linked beads were prepared by dropping dispersed phase of lornoxicam, pectin, and sodium alginate into the dispersion phase of different concentrations of calcium chloride solution followed by aluminium chloride solution. The formulated beads were further coated by Eudragit L & S 100 in the ratio 1 : 2 w/w in order to achieve desired lag time. In vitro release study showed lag time of 5–8 h before release of lornoxicam from the formulated beads. Thus, formulated dual cross

APA, Harvard, Vancouver, ISO, and other styles

More sources

Book chapters on the topic "Lornoxicam"

1

Sahoo, Biswa Mohan, Chandan Kumar Brahma, Bikash Ranjan Jena, et al. "Development of sophisticated RP-HPLC approach for quantifying lornoxicam in API and pharmaceutical formulation." In Advancement in Animal Handling and Generative AI for Pre-clinical Studies. CRC Press, 2025. https://doi.org/10.1201/9781003672869-21.

Full text

APA, Harvard, Vancouver, ISO, and other styles

2

Thakkar, Vaishali, Ankur Patel, Saloni Dalwadi, Hardik Rana, and Tejas Thakkar. "Response Surface and Artificial Neural Network Simulation Used in Dissolution Enhancement of Poorly Soluble Lornoxicam Using Microwave-Assisted Solid Dispersion Technique." In Human-Centric Smart Computing. Springer Nature Singapore, 2024. http://dx.doi.org/10.1007/978-981-99-7711-6_24.

Full text

APA, Harvard, Vancouver, ISO, and other styles

3

"Lornoxicam." In Meyler's Side Effects of Drugs: The International Encyclopedia of Adverse Drug Reactions and Interactions. Elsevier, 2006. http://dx.doi.org/10.1016/b0-44-451005-2/01273-0.

Full text

APA, Harvard, Vancouver, ISO, and other styles

4

"Lornoxicam." In Meyler's Side Effects of Drugs. Elsevier, 2016. http://dx.doi.org/10.1016/b978-0-444-53717-1.00999-9.

Full text

APA, Harvard, Vancouver, ISO, and other styles

5

Ahmed, Mahrous O., and Abdullah A. Al-Badr. "Lornoxicam." In Profiles of Drug Substances, Excipients and Related Methodology. Elsevier, 2011. http://dx.doi.org/10.1016/b978-0-12-387667-6.00006-3.

Full text

APA, Harvard, Vancouver, ISO, and other styles

6

"Lornoxicam." In Drugs Handbook 2012–2013. Bloomsbury Academic, 2011. http://dx.doi.org/10.5040/9781350363595.art-1016.

Full text

APA, Harvard, Vancouver, ISO, and other styles

7

Valentovic, Monica. "Lornoxicam." In xPharm: The Comprehensive Pharmacology Reference. Elsevier, 2007. http://dx.doi.org/10.1016/b978-008055232-3.62054-9.

Full text

APA, Harvard, Vancouver, ISO, and other styles

8

Prasad, Ayya Rajendra, and Bannaravuri Thireesha. "Development and Validation of UV-Spectrophotometric Method for the Determination of Lornoxicam in Microsponges." In Technological Innovation in Pharmaceutical Research Vol. 4. Book Publisher International (a part of SCIENCEDOMAIN International), 2021. http://dx.doi.org/10.9734/bpi/tipr/v4/9506d.

Full text

APA, Harvard, Vancouver, ISO, and other styles

Conference papers on the topic "Lornoxicam"

1

Syrmos, N., S. Κaratzoglou, P. Christoglou, et al. "B176 Lornoxicam as a treatment of geriatric golden age female patients with chronic neck pain." In ESRA Abstracts, 39th Annual ESRA Congress, 22–25 June 2022. BMJ Publishing Group Ltd, 2022. http://dx.doi.org/10.1136/rapm-2022-esra.251.

Full text

APA, Harvard, Vancouver, ISO, and other styles

We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!